Bellevue Healthcare - Directorate Change
03/02/2025 10:41
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250203:nRSC6686Va&default-theme=true
RNS Number : 6686V Bellevue Healthcare Trust PLC 03 February 2025
Bellevue Healthcare Trust plc
(the "Company")
Board Appointments and Succession Planning
Following a comprehensive selection process, conducted using an independent
third-party search firm, the Company is pleased to announce the appointment of
two independent non-executive directors to the Board. Clare Brady and Sarah
MacAulay will join the Board with immediate effect.
Clare is a chartered governance professional with 35 years' experience in
banking and financial services. Clare is Chairman of Fidelity Asian Values plc
and a non-executive director of The Golden Charter Trust Limited. She is
also non-executive director, Audit Committee Chairman and member of the Risk
Committee and Conflicts Committee of M&G Group Limited, M&G Investment
Management Limited and M&G Alternatives Investment Management Limited.
Clare was a non-executive director of Credit Suisse until its merger with UBS.
In her executive career, she was a Director of the International Monetary Fund
("IMF") and prior to that, the Auditor General at the World Bank, based in
Washington D.C. Previously, Clare headed audit and compliance functions at the
Bank of England, Barclays Capital, HSBC and Deutsche Bank.
Sarah has over twenty years of fund management experience based in both London
and Hong Kong, managing unit trusts and institutional assets. She is currently
Chairman of Schroder Asian Total Return Investment Company plc and a
non-executive director of Fidelity Japan Trust plc and Baillie Gifford China
Growth Trust plc. Sarah was formerly a Director of Baring Asset Management
(Asia) Ltd in Hong Kong, Asian Investment Manager at Kleinwort Benson
Investment Management and Eagle Star in London.
The Appointment of Clare Brady and Sarah MacAulay falls to be ratified by
shareholders at the Annual General Meeting ("AGM") of the Company to be held
in April 2025.
Randeep Grewal, Chairman, commented:
"We are delighted to welcome both Clare and Sarah to the Board. They bring a
wealth of oversight and board experience besides familiarity with investment
markets. We are confident that they will both make a valuable contribution to
the Company."
Randeep Grewal and Paul Southgate, who have served on the Board since the
launch of the Company in December 2016, will retire from the Board at the
April 2025 AGM. Kate Bolsover, who joined the Board in July 2021, will become
Chairman following Randeep Grewal's retirement. Clare Brady will assume the
role of Chairman of the Audit Committee at the April 2025 AGM, with Jo Dixon
remaining on the Board as Senior Independent Director until the 2026 AGM.
The Board is engaged in an ongoing search with a head-hunter for another
suitable independent non-executive director to further strengthen the Board.
In addition to Clare Brady and Sarah MacAulay's appointments, the Board
expects to appoint a further non-executive director to succeed Jo Dixon upon
her retirement at the AGM in 2026. The Board is cognisant that they need to
appoint a Parker Review compliant individual and will provide further updates
in due course.
There is no information to be disclosed in respect of UKLR 6.4.8 for Ms Brady
or Ms MacAulay and as at the date of this announcement, they have no
beneficial interests in the ordinary shares of the Company.
LEI: 213800HQ3J3H9YF2UI82
Enquiries:
NSM Funds (UK) Limited
Company Secretary
bellevue@nsm.group (mailto:bellevue@nsm.group)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOAFZGGZGFNGKZM